한국바이오의약품협회

Newsletters

> Newsletters

Vol. 58 (June 19, 2017)

Data 2017-06-19 18:30:05
View 37365

Publication of report on R&D trend of genome engineering technologies

The Ministry of Food and Drug Safety published a report on R&D trend of engineered nuclease technology in which the current development state and regulation related to the technology at the country level.

Genome engineering technology enables the treatment of various incurable diseases fundamentally by editing or modulating genomes for removal of problematic genes or restoration to normal function.

Genome engineering technology will be applied not only to genetic diseases but also to various diseases including cancer, infectious disease, metabolic disorders and autoimmune disease.

Fig 1. Applications of Genome Engineering

(Reference: CMI Development and Application of CRISPR-Cas9 for Genome Engineering, Cell (2014))

Table 1. Current State of CRISPR-Cas9 Application

Industry sector	Product/application	Company
Food	Yogurt,Cheese Crops	Danisco (DuPont) Dow Agrosciences
	Livestock Crops	Recombinetics Cellectis Plant Sciences
Laboratory	Research tools Expression systems Research tools Animal models Research tools Anmal models	System Biosciences Sigma-Aldrich GE Healthcare Sage ThermoFisher Taconic
Sublicensing	Ag, Industrial, Bio	Caribou
Medical	Pharmaceuticals In vitro applications only Target validation Therapeutics Monogenic diseases	Novartis Cellectis AstraZeneca Crispr Therapeutics Sangamo Biosciences
	Therapeutics Therapeutics	Intellia Editas

(Reference: History and market impact on CIRSPR RNA-guided nucleases, ScienceDirect (2015))

The report is expected to contribute to the development of treatment and commercialization of product using genome engineering technology in a preemptive manner for people in relevant industries including researchers, developers, and reviewers.

Major contents

- Overview of Genome Engineering Technology

- Current R&D Status of Genome Engineering Technology on patent, non-clinical research and clinical research

- Related Regulations by country

Fore more details, visit the website of MFDS.

Promotional Video of Global BIO Conference 2017

The Global Bio Conference 2017 (GBC 2017) is an international meeting for experts in the biopharmaceutical industry. This premier event attracts over 2,000 biopharmaceutical leaders from all over the world.
GBC 2017 will take place at the InterContinental Seoul COEX Hotel, Korea from June 28th to 30th, 2017.
The conference is hosted by the Ministry of Food and Drug Safety and organized by the Korea Biomedicine Industry Association.

The conference aims to share the latest development trends and global issues in biopharmaceuticals, and to establisha network of cooperation among leading experts.
The main theme for GBC 2017 is, “Biopharmaceuticals - Future of the Fourth Industrial Revolution.”

In this conference, a variety of topics will be covered such as, vaccines, blood products, DNA recombinant products, cell & gene therapies, human tissues, GMP, biostatistics, and cosmetics. Experts from academic institutes, industry, and regulatory authorities will share the latest regulatory information and biotechnology trends.

Fore more details, visit the website of GBC 2017.

List

Previous	Vol. 57 (June 5, 2017)
Next	Vol. 59 (July 3, 2017)